Gregory Ligozio

1.7k total citations · 1 hit paper
25 papers, 1.3k citations indexed

About

Gregory Ligozio is a scholar working on Rheumatology, Immunology and Surgery. According to data from OpenAlex, Gregory Ligozio has authored 25 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Rheumatology, 8 papers in Immunology and 6 papers in Surgery. Recurrent topics in Gregory Ligozio's work include Rheumatoid Arthritis Research and Therapies (14 papers), Spondyloarthritis Studies and Treatments (12 papers) and Psoriasis: Treatment and Pathogenesis (7 papers). Gregory Ligozio is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (14 papers), Spondyloarthritis Studies and Treatments (12 papers) and Psoriasis: Treatment and Pathogenesis (7 papers). Gregory Ligozio collaborates with scholars based in United States, Switzerland and United Kingdom. Gregory Ligozio's co-authors include Shephard Mpofu, Luminita Pricop, Philip J. Mease, Hanno B. Richards, Désirée van der Heijde, Bruce Kirkham, Iain B. McInnes, Proton Rahman, Christopher T. Ritchlin and Philip G. Conaghan and has published in prestigious journals such as The Lancet, Gastroenterology and PLoS ONE.

In The Last Decade

Gregory Ligozio

25 papers receiving 1.3k citations

Hit Papers

Secukinumab, a human anti-interleukin-17A monoclonal anti... 2015 2026 2018 2022 2015 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
    2015 650 citations Iain B. McInnes, Philip J. Mease et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gregory Ligozio United States 12 699 590 387 386 258 25 1.3k
Nurhan Sutcliffe United Kingdom 21 308 0.4× 645 1.1× 22 0.1× 66 0.2× 290 1.1× 43 1.3k
Ulrike von Arnim Germany 19 226 0.3× 241 0.4× 376 1.0× 15 0.0× 754 2.9× 71 1.3k
A Elewaut Belgium 13 110 0.2× 252 0.4× 82 0.2× 70 0.2× 177 0.7× 40 738
Guy Shalom Israel 15 238 0.3× 174 0.3× 17 0.0× 38 0.1× 150 0.6× 37 699
Rafael Valle‐Oñate Colombia 18 799 1.1× 1.6k 2.6× 8 0.0× 592 1.5× 79 0.3× 59 1.9k
Robert Quinet United States 15 200 0.3× 244 0.4× 17 0.0× 33 0.1× 106 0.4× 40 693
Jessica A. Walsh United States 20 808 1.2× 972 1.6× 6 0.0× 416 1.1× 30 0.1× 101 1.3k
Klas Sjöberg Sweden 22 82 0.1× 55 0.1× 571 1.5× 24 0.1× 343 1.3× 65 1.1k
Costantino Botsios Italy 15 216 0.3× 315 0.5× 12 0.0× 112 0.3× 65 0.3× 26 717
Benjamin Rhodes United Kingdom 14 385 0.6× 368 0.6× 15 0.0× 69 0.2× 75 0.3× 40 776

Countries citing papers authored by Gregory Ligozio

Since Specialization
Citations

This map shows the geographic impact of Gregory Ligozio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gregory Ligozio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gregory Ligozio more than expected).

Fields of papers citing papers by Gregory Ligozio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gregory Ligozio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gregory Ligozio. The network helps show where Gregory Ligozio may publish in the future.

Co-authorship network of co-authors of Gregory Ligozio

This figure shows the co-authorship network connecting the top 25 collaborators of Gregory Ligozio. A scholar is included among the top collaborators of Gregory Ligozio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gregory Ligozio. Gregory Ligozio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jamaludin, Amir, Sarim Ather, Timor Kadir, et al.. (2025). Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets. Lara D. Veeken. 64(10). 5446–5454. 1 indexed citations
2.
Chen, Yao, Yuanhan Mo, Aimee Readie, et al.. (2024). VertXNet: an ensemble method for vertebral body segmentation and identification from cervical and lumbar spinal X-rays. Scientific Reports. 14(1). 3341–3341. 11 indexed citations
3.
Mease, Philip J., Désirée van der Heijde, Bruce Kirkham, et al.. (2022). Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis. Arthritis Research & Therapy. 24(1). 283–283. 1 indexed citations
4.
Pournara, Effie, Matthías Kormáksson, Peter Nash, et al.. (2021). Clinically relevant patient clusters identified by machine learning from the clinical development programme of secukinumab in psoriatic arthritis. RMD Open. 7(3). e001845–e001845. 20 indexed citations
5.
Gottlieb, Alice B., Philip J. Mease, Bruce Kirkham, et al.. (2020). Secukinumab Efficacy in Psoriatic Arthritis. JCR Journal of Clinical Rheumatology. 27(6). 239–247. 19 indexed citations
6.
Heijde, Désirée van der, Philip J. Mease, Robert Landewé, et al.. (2019). Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Lara D. Veeken. 59(6). 1325–1334. 45 indexed citations
7.
Kirkham, Bruce, Philip J. Mease, Peter Nash, et al.. (2018). AB0945 Secukinumab efficacy in patients with active psoriatic arthritis: pooled analysis of four phase 3 trials by prior anti-tnf therapy and concomitant methotrexate use. Annals of the Rheumatic Diseases. 77. 1597–1598. 4 indexed citations
8.
McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2015). Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 386(9999). 1137–1146. 650 indexed citations breakdown →
9.
Heijde, Désirée van der, R. B. M. Landewé, Iain B. McInnes, et al.. (2015). THU0414 Secukinumab Inhibits Radiographic Progression in Patients with Psoriatic Arthritis: Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (Future 1). Annals of the Rheumatic Diseases. 74. 347–348. 5 indexed citations
10.
McInnes, Iain B., Bruce Kirkham, Arthur Kavanaugh, et al.. (2015). THU0425 Secukinumab Improves Signs and Symptoms of Active Psoriatic Arthritis in a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using a Subcutaneous Dosing Regimen (Future 2). Annals of the Rheumatic Diseases. 74. 352–353. 1 indexed citations
11.
McInnes, Iain B., Philip J. Mease, Bruce Kirkham, et al.. (2014). Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing. Data Archiving and Networked Services (DANS). 66(12). 3529–3529. 19 indexed citations
12.
Landewé, Robert, Iain B. McInnes, Philip G. Conaghan, et al.. (2014). Secukinumab, a Monoclonal Antibody to Interleukin-17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study. Data Archiving and Networked Services (DANS). 66. 42–43. 16 indexed citations
13.
Genovese, Mark C., Patrick Durez, Hanno B. Richards, et al.. (2014). One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study. The Journal of Rheumatology. 41(3). 414–421. 83 indexed citations
14.
Chey, William D., Colin W. Howden, Jan Tack, Gregory Ligozio, & David L. Earnest. (2009). Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies. Digestive Diseases and Sciences. 55(3). 684–697. 13 indexed citations
15.
Vakil, Nimish, Loren Laine, Nicholas J. Talley, et al.. (2008). Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. The American Journal of Gastroenterology. 103(8). ???–???. 86 indexed citations
16.
Chey, William D., et al.. (2008). Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial. The American Journal of Gastroenterology. 103(5). 1217–1225. 47 indexed citations
17.
Cowan, Alan, David L. Earnest, Gregory Ligozio, & Mikhail Rojavin. (2005). Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod. European Journal of Pharmacology. 517(1-2). 127–131. 14 indexed citations
18.
Novick, J., Philip B. Miner, Richard A. Krause, et al.. (2002). A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics. 16(11). 1877–1888. 240 indexed citations
19.
Nault, Brigitte, et al.. (2001). Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS). Gastroenterology. 120(5). A284–A284. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nurhan Sutcliffe Breakdown of academic impact, for papers by Ulrike von Arnim Breakdown of academic impact, for papers by A Elewaut Breakdown of academic impact, for papers by Guy Shalom Breakdown of academic impact, for papers by Rafael Valle‐Oñate Breakdown of academic impact, for papers by Robert Quinet Breakdown of academic impact, for papers by Jessica A. Walsh Breakdown of academic impact, for papers by Klas Sjöberg Breakdown of academic impact, for papers by Costantino Botsios Breakdown of academic impact, for papers by Benjamin Rhodes
Rankless by CCL
2026